AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32678005 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention led by trained nurse facilitators, consisting of an information brochure and two ACP conversations
Number of subjects: 0
Study 32678005 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for nurses
Number of subjects: 0
Study 32678005 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with caregivers
Number of subjects: 0
Study 35565656 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch- and sucrose-reduced diet (SSRD)
Number of subjects: 105
Study 35565656 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet (Control)
Number of subjects: 105
Study 33774169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of acetaminophen orally every 6 hours for 1 day prior to and after surgery, then every 8 hours during postoperative days 2-5, with the option to take 5 mg of oxycodone every 6 hours as needed after surgery.
Number of subjects: 57
Study 33774169 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of oxycodone every 6 hours as needed and 1000 mg of acetaminophen orally every 6 hours as needed after surgery.
Number of subjects: 57
Study 33774169 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of oxycodone every 6 hours as needed without any additional acetaminophen after surgery.
Number of subjects: 57
Study 35358740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan‐S
Number of subjects: 674
Study 35358740 — intervention group
Group type: COMPARATOR
Intervention: dinoprostone
Number of subjects: 674
Study 34645165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 34645165 — intervention group
Group type: COMPARATOR
Intervention: HIPEC
Number of subjects: 0
Study 34645165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS)
Number of subjects: 0
Study 32791583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus myringotomy (group A)
Number of subjects: 0
Study 32791583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus tympanostomy tube insertion (group B)
Number of subjects: 0
Study 34797431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered implant (TI)
Number of subjects: 20
Study 34797431 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight implant (SI)
Number of subjects: 20
Study 33712246 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Collars (NC+)
Number of subjects: 125
Study 33712246 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging (NC-)
Number of subjects: 125
Study 34051345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HP + LED/laser
Number of subjects: 20
Study 34051345 — intervention group
Group type: COMPARATOR
Intervention: 35% HP
Number of subjects: 20
Study 35975308 — intervention group
Group type: EXPERIMENTAL
Intervention: GlyNAC supplementation for 16 weeks
Number of subjects: 24
Study 35975308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous alanine) for 16 weeks
Number of subjects: 24
Study 34976328 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil anesthesia
Number of subjects: 120
Study 34976328 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil anesthesia
Number of subjects: 120
Study 32741354 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron and folate supplement for adolescent girls
Number of subjects: 405
Study 32741354 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming programme twice per year
Number of subjects: 405
Study 35394898 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Polio Vaccine (IPV)
Number of subjects: 1146
Study 33832092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 pulses of rTMS
Number of subjects: 29
Study 33832092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 pulses of rTMS
Number of subjects: 29
Study 33832092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 pulses of rTMS
Number of subjects: 29
Study 35325467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoid (10 mg/kg methylprednisolone)
Number of subjects: 53
Study 35325467 — intervention group
Group type: COMPARATOR
Intervention: Low-dose glucocorticoid (8 mg dexamethasone)
Number of subjects: 53
Study 32882163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg after 1 month of 10 mg prasugrel plus 100 mg aspirin daily (de-escalation group)
Number of subjects: 2338
Study 32882163 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg plus 100 mg aspirin daily (conventional group)
Number of subjects: 2338
Study 32882163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel-based de-escalation therapy
Number of subjects: 2338
Study 33887247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive host-directed therapies
Number of subjects: 0
Study 33887247 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36206786 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy
Number of subjects: 133
Study 36206786 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilation
Number of subjects: 133
Study 32914830 — intervention group
Group type: EXPERIMENTAL
Intervention: SNS genetic risk‐by‐neighborhood social life interaction
Number of subjects: 228
Study 32914830 — intervention group
Group type: EXPERIMENTAL
Intervention: SNS genetic risk‐by‐informal social control interaction
Number of subjects: 228
Study 32914830 — intervention group
Group type: EXPERIMENTAL
Intervention: SNS genetic risk‐by‐neighborhood satisfaction interaction
Number of subjects: 228
Study 32249441 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 26
Study 32249441 — intervention group
Group type: COMPARATOR
Intervention: Blood clot (BLC)
Number of subjects: 26
Study 34641873 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA methylation classifier
Number of subjects: 401
Study 32535263 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (0.5 mg/kg intravenous after induction of anesthesia)
Number of subjects: 0
Study 32535263 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study 33547665 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT + SRP
Number of subjects: 60
Study 33547665 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 33547665 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 32448374 — intervention group
Group type: EXPERIMENTAL
Intervention: ADvisor internet programmes plus three patient telephone calls from a psychological wellbeing practitioner
Number of subjects: 402
Study 32448374 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 402
Study 35790326 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported home exercise programme
Number of subjects: 210
Study 35790326 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face physiotherapy
Number of subjects: 210
Study 34028550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification with support
Number of subjects: 361
Study 34028550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification with competition
Number of subjects: 361
Study 34028550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification with collaboration
Number of subjects: 361
Study 34028550 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 361
Study 32350145 — intervention group
Group type: EXPERIMENTAL
Intervention: DS + SS
Number of subjects: 23
Study 32350145 — intervention group
Group type: EXPERIMENTAL
Intervention: DS + FR
Number of subjects: 23
Study 32350145 — intervention group
Group type: EXPERIMENTAL
Intervention: DS + VFR
Number of subjects: 23
Study 35617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon triamcinolone acetonide (TAAC) injection (4mg) with MMC‐TRAB
Number of subjects: 75
Study 35617211 — intervention group
Group type: COMPARATOR
Intervention: Standard MMC‐TRAB
Number of subjects: 75
Study 34914215 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-suture knot
Number of subjects: 120
Study 34914215 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-suture knot
Number of subjects: 120
Study 34914215 — intervention group
Group type: COMPARATOR
Intervention: Traditional circumcision without suture knot
Number of subjects: 120
Study 34331235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 1000
Study 33065642 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 1067
Study 33065642 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1067
Study 34489744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergen 4-day treatment (B4DT)
Number of subjects: 48
Study 34489744 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 48
Study 34489744 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 48
Study 32552721 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner (GP) coordination of healthcare
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Sex (male vs. female)
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Morbidity
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Education (high vs. low)
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Household net adjusted disposable income
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Regional category (urban areas)
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Regional category (environs)
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Healthcare utilisation (each GP contact)
Number of subjects: 811
Study 32552721 — intervention group
Group type: COMPARATOR
Intervention: Healthcare utilisation (each contact to a medical specialist)
Number of subjects: 811
Study 36458119 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual + aerobic exercise training (40-min twice a week for 8 weeks)
Number of subjects: 94
Study 36458119 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 94
Study 36458119 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual + aerobic exercise training
Number of subjects: 94
Study 32576199 — intervention group
Group type: EXPERIMENTAL
Intervention: ENG-releasing subdermal contraceptive implant
Number of subjects: 100
Study 32576199 — intervention group
Group type: COMPARATOR
Intervention: Other contraceptive methods
Number of subjects: 100
Study 35202795 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-tDCS targeting primary motor cortex and dorsolateral prefrontal cortex
Number of subjects: 40
Study 35202795 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 40
Study 35202795 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Number of subjects: 40
Study 33461986 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record alerts for acute kidney injury
Number of subjects: 6030
Study 33461986 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6030
Study 34952813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense regimen of five sessions/week for 3 weeks
Number of subjects: 0
Study 34952813 — intervention group
Group type: COMPARATOR
Intervention: Non-dense regimen of three sessions/week for 5 weeks (Control)
Number of subjects: 0
Study 32451288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) plus pharmacotherapy on demand
Number of subjects: 86
Study 32451288 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 86
Study 35197493 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleguided multidisciplinary intervention
Number of subjects: 58
Study 35197493 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus access to an educational website
Number of subjects: 58
Study 35197493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 33319739 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200 (1 × 10^9 CFU)
Number of subjects: 172
Study 33319739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 33319739 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200
Number of subjects: 172
Study 35857659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 847
Study 35857659 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 847
Study 32502772 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-oxide impregnated wound dressing (study group)
Number of subjects: 324
Study 32502772 — intervention group
Group type: COMPARATOR
Intervention: Non-copper wound dressing (control group)
Number of subjects: 324
Study 34998000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR injections
Number of subjects: 90
Study 34998000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG injection
Number of subjects: 90
Study 34998000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional candida antigen injection
Number of subjects: 90
Study 35737193 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + ASD
Number of subjects: 0
Study 35737193 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 33840228 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 PUFAs (eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid)
Number of subjects: 203
Study 33840228 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 PUFAs (top quartile)
Number of subjects: 203
Study 33840228 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid
Number of subjects: 203
Study 35932419 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum‐residual refractive astigmatism group
Number of subjects: 90
Study 35932419 — intervention group
Group type: COMPARATOR
Intervention: Steep‐axis group
Number of subjects: 90
Study 34580639 — intervention group
Group type: EXPERIMENTAL
Intervention: Finishing and polishing procedures applied to Filtek™ Bulk Fill composite
Number of subjects: 0
Study 34580639 — intervention group
Group type: EXPERIMENTAL
Intervention: Finishing and polishing procedures applied to Dyract XP compomer
Number of subjects: 0
Study 34033939 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy (perio-green, 0.1 mg/ml)
Number of subjects: 20
Study 34033939 — intervention group
Group type: COMPARATOR
Intervention: scaling and root planing (control group)
Number of subjects: 20
Study 34033939 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy
Number of subjects: 20
Study 34033939 — intervention group
Group type: EXPERIMENTAL
Intervention: microbiome analysis in test sites
Number of subjects: 20
Study 35928098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium with hyoscine-N-butyl bromide (HBB)
Number of subjects: 64
Study 35928098 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium alone (placebo group)
Number of subjects: 64
Study 35928098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (diclofenac potassium with HBB vs placebo)
Number of subjects: 64
Study 34464752 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation combining a mixed-nutrient supplement with structured supervised and home-based exercise training, and relaxation strategies (Prehab)
Number of subjects: 34
Study 34464752 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care (Control)
Number of subjects: 34
Study 35897381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 44
Study 35897381 — intervention group
Group type: EXPERIMENTAL
Intervention: ShockWave-Intravascular-Lithotripsy (S-IVL)
Number of subjects: 44
Study 34647106 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTACH™ program (10-week psycho-educational intervention)
Number of subjects: 20
Study 34647106 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 20
Study 36094967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 224
Study 36094967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 32338106 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SPN-810 (12/18 mg/day)
Number of subjects: 95
Study 32338106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose SPN-810 (24/36 mg/day)
Number of subjects: 95
Study 32338106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SPN-810 (36/54 mg/day)
Number of subjects: 95
Study 32338106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 33185468 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg SHP465 mixed amphetamine salts (MAS) once daily
Number of subjects: 89
Study 33185468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 35606544 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 88
Study 35606544 — intervention group
Group type: COMPARATOR
Intervention: Sigmoidectomy
Number of subjects: 88
Study 34323334 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus 3 semi-personalised dietary mobile phone text messages per week over a 6 month period
Number of subjects: 130
Study 34323334 — intervention group
Group type: COMPARATOR
Intervention: Usual care (in-person dietary counselling)
Number of subjects: 130
Study 35426742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians responding to empathic opportunities during encounters
Number of subjects: 71
Study 35426742 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic communication patterns
Number of subjects: 71
Study 34684055 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD and IPC (compression of 60 to 80 mmHg)
Number of subjects: 30
Study 34684055 — intervention group
Group type: COMPARATOR
Intervention: MLD and sham IPC (compression of <30 mmHg)
Number of subjects: 30
Study 34684055 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD and IPC (experimental group)
Number of subjects: 30
Study 32902413 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (JAK inhibitor)
Number of subjects: 20
Study 34391573 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy plus prophylactic central compartment lymph node dissection (TTx+pCND)
Number of subjects: 101
Study 34391573 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy (TTx)
Number of subjects: 101
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' spiritual care practices
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Private prayer for patients
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of spiritual/religious topics with patients
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement for patients to pray
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to clergy or religious leaders
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Praying with patients
Number of subjects: 215
Study 34090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of spiritual services provided
Number of subjects: 215
Study 36202719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific osteosynthesis
Number of subjects: 58
Study 36202719 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteosynthesis
Number of subjects: 58
Study 33517727 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular sparing (CS) technique (n = 104)
Number of subjects: 190
Study 33517727 — intervention group
Group type: COMPARATOR
Intervention: Capsular resection (CR) technique (n = 115)
Number of subjects: 190
Study 33901247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week neck-only rehabilitation programme
Number of subjects: 25
Study 32142492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.05 mg/mL + nalbuphine 0.5 mg/mL (group LN)
Number of subjects: 114
Study 32142492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.05 mg/mL + nalbuphine 0.7 mg/mL (group MN)
Number of subjects: 114
Study 32142492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.05 mg/mL + nalbuphine 0.9 mg/mL (group HN)
Number of subjects: 114
Study 35172888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) at least 1 hour/day, 4 times a week for 1 year, in addition to usual care.
Number of subjects: 100
Study 35172888 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 35172888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 100
Study 33550905 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 138
Study 33550905 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR A1298C polymorphism
Number of subjects: 138
Study 33550905 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage disequilibrium analysis
Number of subjects: 138
Study 33550905 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR A1298C genotype prevalence
Number of subjects: 138
Study 32572017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 86
Study 32572017 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 86
Study 32385741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20 sessions over 4 weeks)
Number of subjects: 31
Study 32385741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Number of subjects: 31
Study 32385741 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 31
Study 36276997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery (successful)
Number of subjects: 738